CCCC Stock Price, C4 Therapeutics Inc Quote, Chart

Market Summary

USD5.69-0.28

Market Closed

-4.69%

CCCC Stock Price

View Fullscreen

CCCC RSI Chart

CCCC Valuation

Market Cap

391.5M

Price/Earnings (Trailing)

-3.11

Price/Sales (Trailing)

19.54

EV/EBITDA

-2.46

Price/Free Cashflow

-4.21

CCCC Price/Sales (Trailing)

CCCC Profitability

EBT Margin

-617.15%

Return on Equity

-48.81%

Return on Assets

-31.65%

Free Cashflow Yield

-23.74%

CCCC Fundamentals

CCCC Revenue

Revenue (TTM)

20.0M

Rev. Growth (Yr)

-19.15%

Rev. Growth (Qtr)

-6.81%

CCCC Earnings

Earnings (TTM)

-126.1M

Earnings Growth (Yr)

18.46%

Earnings Growth (Qtr)

18.4%

Breaking Down CCCC Revenue

Last 7 days

-7.6%

Last 30 days

-17.2%

Last 90 days

-28.7%

Trailing 12 Months

78.9%

How does CCCC drawdown profile look like?

CCCC Financial Health

Current Ratio

5.08

CCCC Investor Care

Shares Dilution (1Y)

40.24%

Diluted EPS (TTM)

-2.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	20.0M	0	0	0
2023	27.2M	16.0M	20.3M	20.8M
2022	46.0M	50.1M	48.3M	31.1M
2021	33.8M	33.9M	34.0M	45.8M
2020	24.3M	27.3M	30.2M	33.2M
2019	0	0	0	21.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of C4 Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	anderson kenneth carl	acquired	11,250	8.1	1,389	-
Apr 01, 2024	grogan donna roy	acquired	13,745	8.1	1,697	-
Apr 01, 2024	dubin glenn	acquired	10,999	8.1	1,358	-
Feb 15, 2024	hirsch andrew	sold (taxes)	-51,824	7.9	-6,560	president & ceo
Feb 14, 2024	mossler mark	acquired	-	-	18,290	chief accounting officer
Feb 14, 2024	adams kendra	acquired	-	-	36,700	chief financial officer
Feb 14, 2024	reyno leonard	acquired	-	-	36,700	chief medical officer
Feb 14, 2024	siegel jolie	acquired	-	-	27,300	chief legal officer
Feb 14, 2024	boyle scott n	acquired	-	-	27,300	chief business officer
Feb 14, 2024	fisher stewart	acquired	-	-	27,300	chief scientific officer

Which funds bought or sold CCCC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-72.76	-680,380	442,111	-%
May 16, 2024	Arete Wealth Advisors, LLC	added	18.17	288,719	696,084	0.06%
May 15, 2024	MARSHALL WACE, LLP	reduced	-86.94	-5,147,210	1,198,080	-%
May 15, 2024	Point72 Asset Management, L.P.	reduced	-53.78	-3,675,800	7,405,880	0.02%
May 15, 2024	D. E. Shaw & Co., Inc.	added	103	2,680,200	4,056,760	-%
May 15, 2024	CITADEL ADVISORS LLC	added	608	2,466,250	2,733,010	-%
May 15, 2024	Soleus Capital Management, L.P.	added	33.93	9,716,620	20,090,000	1.49%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	1,028	9,826,400	10,467,700	-%
May 15, 2024	FARALLON CAPITAL MANAGEMENT LLC	new	-	228,760	228,760	-%
May 15, 2024	ALGERT GLOBAL LLC	sold off	-100	-158,000	-	-%

Are Funds Buying or Selling CCCC?

Are funds buying CCCC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CCCC

No. of Funds

Unveiling C4 Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	state street corp	10.43%	7,153,280	SC 13G
Mar 08, 2024	wasatch advisors lp	-	0	SC 13G/A
Feb 14, 2024	lynx1 capital management lp	6.4%	3,134,396	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	5.2%	2,558,480	SC 13G/A
Feb 14, 2024	rtw investments, lp	0%	0	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Feb 05, 2024	soleus capital master fund, l.p.	5.2%	2,555,996	SC 13G
Feb 02, 2024	soleus capital master fund, l.p.	3.7%	1,835,996	SC 13G/A
Jan 12, 2024	betta investment (hong kong) ltd.	8.1%	5,567,928	SC 13G
Jan 04, 2024	point72 asset management, l.p.	4.7%	2,312,059	SC 13G

Recent SEC filings of C4 Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 30, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	SC 13G	Major Ownership Report
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to C4 Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

C4 Therapeutics Inc News

Latest updates

C4 Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Revenue	-6.8%	3,039,000	3,261,000	11,072,000	2,664,000	3,759,000	2,854,000	6,754,000	13,834,000	7,654,000	20,078,000	8,500,000	9,781,000	7,426,000	8,262,000	8,447,000	9,670,000	6,816,000	6,090,000	5,364,000
Operating Expenses	-13.3%	35,258,000	40,688,000	38,880,000	40,232,000	39,987,000	41,147,000	39,242,000	41,218,000	39,023,000	35,333,000	32,754,000	31,897,000	27,935,000	27,165,000	26,796,000	20,529,000	19,154,000	-	15,365,000
S&GA Expenses	-100.0%	-	10,297,000	10,533,000	10,306,000	10,945,000	10,495,000	9,579,000	9,895,000	12,820,000	8,782,000	8,452,000	8,611,000	7,409,000	6,732,000	2,861,000	2,769,000	2,842,000	-	2,417,000
R&D Expenses	-25.9%	22,533,000	30,391,000	28,347,000	29,926,000	29,042,000	30,652,000	29,663,000	31,323,000	26,203,000	26,551,000	24,302,000	23,286,000	20,526,000	20,433,000	23,935,000	17,760,000	16,312,000	-	12,948,000
EBITDA Margin	3.1%	-6.05	-6.25	-6.22	-8.23	-4.86	-3.64	-2.09	-1.83	-1.99	-1.77	-2.58	-2.51	-	-	-	-	-	-	-
Interest Expenses	-	-	-	138,000	422,000	430,000	421,000	375,000	355,000	473,000	238,000	363,000	349,000	358,000	-	-	-	-	-	-
Income Taxes	-100.0%	-	280,000	1,003,000	-	-	-	-	-	-	-	-	-	-	-124,000	-167,000	-168,000	-167,000	-	650,000
Earnings Before Taxes	17.7%	-28,361,000	-34,477,000	-26,034,000	-	-34,780,000	-37,185,000	-31,958,000	-	-31,620,000	-15,658,000	-24,683,000	-22,580,000	-20,971,000	-21,919,000	-22,002,000	-10,961,000	-12,079,000	-	-9,444,000
EBT Margin	3.3%	-6.17	-6.38	-6.39	-8.46	-4.98	-3.74	-2.15	-1.89	-2.05	-1.83	-2.65	-2.58	-	-	-	-	-	-	-
Net Income	18.4%	-28,361,000	-34,754,000	-27,037,000	-35,922,000	-34,780,000	-37,185,000	-31,958,000	-27,412,000	-31,620,000	-15,658,000	-24,683,000	-22,580,000	-20,971,000	-21,795,000	-21,835,000	-10,793,000	-11,912,000	-	-10,094,000
Net Income Margin	1.4%	-6.29	-6.38	-6.63	-8.72	-4.83	-4.12	-2.21	-1.98	-2.05	-1.83	-2.65	-2.57	-	-	-	-	-	-	-
Free Cashflow	25.0%	-18,118,000	-24,166,000	-31,307,000	-19,359,000	-33,714,000	-30,618,000	-31,325,000	-22,724,000	-26,768,000	-25,780,000	-18,358,000	-18,749,000	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	5.8%	398	376	333	375	396	431	461	492	515	507	508	528	374	400	229	118
Current Assets	3.1%	280	271	224	274	278	288	325	318	303	326	412	478	322	381	209	97.00
Cash Equivalents	-26.5%	93.00	127	61.00	45.00	49.00	30.00	50.00	57.00	46.00	79.00	163	281	95.00	184	63.00	91.00
Net PPE	-5.3%	7.00	7.00	7.00	8.00	8.00	7.00	7.00	6.00	3.00	3.00	3.00	4.00	4.00	3.00	4.00	4.00
Liabilities	7.5%	140	130	117	141	134	142	143	148	151	117	109	112	110	119	129	119
Current Liabilities	28.6%	55.00	43.00	30.00	48.00	39.00	45.00	45.00	46.00	47.00	51.00	49.00	44.00	38.00	44.00	40.00	34.00
Long Term Debt	-	-	-	-	-	9.00	9.00	9.00	10.00	10.00	11.00	11.00	10.00	10.00	10.00	10.00	-
LT Debt, Current	-	-	-	-	10.00	2.00	2.00	2.00	1.00	1.00	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	9.00	9.00	9.00	10.00	10.00	11.00	11.00	10.00	10.00	10.00	10.00	-
Shareholder's Equity	4.9%	258	246	216	234	262	289	318	345	365	390	399	416	264	281	-	-
Retained Earnings	-5.4%	-556	-528	-493	-466	-430	-395	-358	-326	-299	-267	-252	-227	-204	-183	-162	-117
Additional Paid-In Capital	5.3%	815	775	711	702	696	689	682	676	668	658	651	644	469	465	6.00	6.00
Shares Outstanding	13.7%	69.00	60.00	49.00	49.00	49.00	49.00	49.00	49.00	49.00	49.00	48.00	43.00	-	-	-	-
Float	-	-	-	-	130	-	-	-	201	-	-	-	1,278	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	24.5%	-18,118	-24,009	-30,707	-18,997	-33,125	-29,128	-28,020	-22,195	-26,596	-25,671	-18,358	-18,002	-24,934	-21,593	-14,396	-14,594	-16,666	-	-
Share Based Compensation	-2.3%	6,215	6,359	8,200	6,425	6,251	6,919	6,011	8,148	8,938	6,353	6,086	5,228	3,845	2,719	436	161	116	-	-
Cashflow From Investing	-267.1%	-53,396	31,945	57,725	15,148	53,531	9,284	19,914	33,228	-4,004	-59,413	-100,627	32,434	-61,730	-54,167	-32,321	-103,833	-184	-	-
Cashflow From Financing	-40.0%	34,583	57,672	-10,753	-746	-684	47.00	361	259	480	466	584	170,501	-151	194,053	2,499	152,224	156	-	-
Buy Backs	-	109	-	16.00	-	94.00	-	-	-	-	-	-	-	-	-16.00	86.00	-78.00	202	-	6.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CCCC Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue from collaboration agreements	$ 3,039	$ 3,759
Operating expenses:
Research and development	22,533	29,042
General and administrative	10,288	10,945
Restructuring	2,437	0
Total operating expenses	35,258	39,987
Loss from operations	(32,219)	(36,228)
Other income (expense), net:
Interest expense and amortization of long-term debt − related party	0	(606)
Interest and other income, net	3,858	2,054
Total other income (expense), net	3,858	1,448
Loss before income taxes	(28,361)	(34,780)
Income tax expense	0	0
Net loss	$ (28,361)	$ (34,780)
Net loss per share − basic (in dollars per share)	$ (0.41)	$ (0.71)
Net loss per share − diluted (in dollars per share)	$ (0.41)	$ (0.71)
Weighted-average number of shares used in computed net loss per share − basic	68,432,168	49,032,319
Weighted-average number of shares used in computed net loss per share − diluted	68,432,168	49,032,319
Other comprehensive income (loss)
Unrealized (loss) gain on marketable securities	$ (253)	$ 1,667
Comprehensive loss	$ (28,614)	$ (33,113)
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Collaborative Arrangement [Member]	Collaborative Arrangement [Member]

CCCC Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 89,659	$ 126,590
Marketable securities, current	168,533	127,091
Accounts receivable	13,599	11,799
Prepaid expenses and other current assets	7,801	5,709
Total current assets	279,592	271,189
Marketable securities, non-current	40,975	28,008
Property and equipment, net	6,756	7,132
Right-of-use asset	62,377	63,956
Restricted cash	3,443	3,443
Other assets	5,228	2,723
Total assets	398,371	376,451
Current liabilities:
Accounts payable	1,630	1,446
Accrued expenses and other current liabilities	12,891	20,630
Deferred revenue, current	35,142	15,471
Operating lease liability, current	5,355	5,219
Total current liabilities	55,018	42,766
Deferred revenue, net of current	20,706	21,814
Operating lease liability, net of current	64,365	65,757
Total liabilities	140,089	130,337
Commitments and contingencies (see Note 11)
Stockholders’ equity:
Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized, and no shares issued or outstanding as of March 31, 2024 and December 31, 2023, respectively	0	0
Common stock, par value of $0.0001 per share; 150,000,000 shares authorized, and 68,778,591 and 60,467,188 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	7	6
Additional paid-in capital	815,399	774,618
Accumulated other comprehensive loss	(380)	(127)
Accumulated deficit	(556,744)	(528,383)
Total stockholders’ equity	258,282	246,114
Total liabilities and stockholders’ equity	$ 398,371	$ 376,451

About C4 Therapeutics Inc

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

CEO	Mr. Andrew J. Hirsch M.B.A.
WEBSITE	c4therapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	146

C4 Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for C4 Therapeutics Inc? What does CCCC stand for in stocks?

CCCC is the stock ticker symbol of C4 Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of C4 Therapeutics Inc (CCCC)?

As of Fri May 17 2024, market cap of C4 Therapeutics Inc is 391.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CCCC stock?

You can check CCCC's fair value in chart for subscribers.

What is the fair value of CCCC stock?

You can check CCCC's fair value in chart for subscribers. The fair value of C4 Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of C4 Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CCCC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is C4 Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CCCC is over valued or under valued. Whether C4 Therapeutics Inc is cheap or expensive depends on the assumptions which impact C4 Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CCCC.

What is C4 Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CCCC's PE ratio (Price to Earnings) is -3.11 and Price to Sales (PS) ratio is 19.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CCCC PE ratio will change depending on the future growth rate expectations of investors.